Last reviewed · How we verify
Platinum Compound
Platinum-based chemotherapy agent that binds to DNA, inhibiting cancer cell replication
Platinum-based chemotherapy agent that binds to DNA, inhibiting cancer cell replication Used for Ovarian cancer, Lung cancer, Breast cancer.
At a glance
| Generic name | Platinum Compound |
|---|---|
| Also known as | Platinum Agents, Platinum-Based Chemotherapeutic Agent |
| Sponsor | SWOG Cancer Research Network |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Platinum compounds work by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Approved indications
- Ovarian cancer
- Lung cancer
- Breast cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Kidney damage
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platinum Compound CI brief — competitive landscape report
- Platinum Compound updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI